World First: Japan Trials Revolutionary Parkinson's Therapy

In a significant medical advancement, a patient in Japan has received a world-first stem-cell therapy for Parkinson's disease. Sumitomo Pharma's innovative treatment, conditionally approved in March, involves transplanting millions of induced Pluripotent Stem (iPS) cells into the brain.

The pioneering procedure was performed at Kyoto University Hospital in October. These iPS cells, capable of becoming any cell type, are developed into dopamine-producing cells, which are typically lost in Parkinson's patients. This therapy offers a potential new avenue for treating the chronic neurological disorder.

Clinical trials involving seven patients aged 50 to 69 demonstrated safety, with no major adverse effects reported over a two-year monitoring period. Notably, four participants showed improvements in their Parkinson's symptoms. Sumitomo Pharma plans to treat between 20 to 30 patients by March 2029.

This groundbreaking treatment will seek full approval in Japan upon confirmation of its safety and efficacy over the next seven years. Concurrently, a clinical trial for the therapy is underway in the United States, indicating a broader global outlook for this Parkinson's treatment.